for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Virbac SA

VIRB.PA

Latest Trade

433.00EUR

Change

11.00(+2.61%)

Volume

10,541

Today's Range

414.00

 - 

433.50

52 Week Range

199.00

 - 

433.50

As of on the Euronext Paris ∙ Minimum 15 minute delay

Latest Developments

Virbac Q3 Revenue Up At 288.2 Million Euros

Oct 18 (Reuters) - Virbac SA <VIRB.PA>::Q3 REVENUE EUR 288.2 MILLION VERSUS EUR 235.6 MILLION YEAR AGO.NOW ANTICIPATES LIKE-FOR-LIKE REVENUE GROWTH (EXCLUDING IMPACT OF SENTINEL SALE) OF 16% TO 18%.ESTIMATES IMPACT OF PRODUCTS ACQUIRED FROM ELANCO (CLOMICALM AND ITRAFUNGOL) AND FROM IVET (US PETFOOD) COULD REPRESENT APPROXIMATELY 1.5 PERCENTAGE POINTS OF REVENUE GROWTH.ANTICIPATES UNFAVORABLE IMPACT OF EXCHANGE RATES ON REVENUE OF APPROXIMATELY EUR 10 MILLION ASSOCIATED WITH CURRENCY DEPRECIATION.DEBT RELIEF SHOULD BE AROUND EUR 60 MILLION FOR THE YEAR AT CONSTANT SCOPE AND EXCHANGE RATES.

Virbac, Jectas Innovators Sign Agreement For Development Of Animal Health Vaccine

Sept 29 (Reuters) - Virbac SA <VIRB.PA>::VIRBAC AND JECTAS INNOVATORS SIGN AN AGREEMENT.ANNOUNCE THE SIGNATURE OF A COLLABORATIVE AGREEMENT FOR THE DEVELOPMENT OF ANIMAL HEALTH VACCINE(S).

Virbac H1 Revenue Up At Eur 529.4 Mln

Sept 15 (Reuters) - Virbac SA <VIRB.PA>::SIGNIFICANT INCREASE IN OPERATING PROFIT FROM ORDINARY ACTIVITIES FOR THE FIRST HALF OF 2021 DUE TO THE SOUND MARKET PERFORMANCE AND DYNAMISM OF OUR BUSINESS.H1 NET PROFIT FROM ORDINARY ACTIVITIES WAS EUR 74.4 MILLION, UP 38.9% COMPARED TO FIRST HALF OF 2020.H1 CURRENT OPERATING PROFIT BEFORE DEPRECIATION OF ASSETS ARISING FROM ACQUISITIONS AMOUNTS TO EUR 105.3 MILLION.H1 REVENUE EUR 529.4 MILLION VERSUS EUR 478.3 MILLION YEAR AGO.WE CURRENTLY ANTICIPATE LIKE-FOR-LIKE REVENUE GROWTH (EXCLUDING IMPACT OF SALE OF SENTINEL) OF 14% TO 17%.VIRBAC SA SEES FY RATIO OF "CURRENT OPERATING PROFIT BEFORE DEPRECIATION OF ASSETS ARISING FROM ACQUISITIONS'' OVER "REVENUE" OF AROUND 16% AT CER.

Virbac Buys 15% Of Shares Of Centrovet For $17.7 Million

Sept 13 (Reuters) - Virbac SA <VIRB.PA>::REG-VIRBAC : AQUACULTURE : VIRBAC STRENGTHENS ITS POSITION IN CENTROVET.WE HAVE BOUGHT 15% OF SHARES OF CENTROVET GROUP, THUS INCREASING OUR STAKE TO 66%, WHILE RETAINING POSSIBILITY OF SUBSEQUENTLY ACQUIRING ALL OR PART OF REMAINING SHARES.CONSIDERATION PAID FOR ACQUISITION OF THIS STAKE IS US $17.7 MILLION, PAID IN FULL AND IN CASH UPON CLOSING.TRANSACTION WILL HAVE LIMITED IMPACT ON FINANCIAL STATEMENTS OF OUR GROUP.

Virbac Announces FDA Approval Of New Cancer Treatment For Dogs

Aug 16 (Reuters) - VIRBAC SA <VIRB.PA>::VIRBAC ANNOUNCES FDA APPROVAL OF NEW CANCER TREATMENT FOR DOGS DERIVED FROM AUSTRALIAN RAINFOREST PLANT.ANNOUNCES BREAKTHROUGH DRUG STELFONTA (TIGILANOL TIGLATE INJECTION) HAS BEEN APPROVED BY U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR TREATING CANINE MAST CELL TUMORS IN DOG.

Virbac H1 Revenue Rises To 529.4 Million Euros

July 20 (Reuters) - Virbac SA <VIRB.PA>::H1 REVENUE ROSE 21.3 PERCENT TO 529.4 MILLION EUR.SECOND-QUARTER REVENUE HIT EUR 262.9 MILLION, A STEEP +18.3% INCREASE.

Virbac Raises Its Outlook For 2021

July 5 (Reuters) - Virbac SA <VIRB.PA>::DRIVEN BY VERY SOLID PERFORMANCE IN ALL AREAS AND A VERY DYNAMIC MARKET, RAISES OUTLOOK FOR 2021.WE CURRENTLY ANTICIPATE REVENUE GROWTH AT CONSTANT RATES AND SCOPE BETWEEN 10% AND 14%.SEES 2021 RATIO OF "CURRENT OPERATING PROFIT, BEFORE DEPRECIATION OF ASSETS ARISING FROM ACQUISITIONS" OVER "REVENUE" AROUND 15% AT CONSTANT EXCHANGE RATES.SAYS WE ANTICIPATE AN UNFAVORABLE IMPACT OF EXCHANGE RATES ON REVENUE OF APPROXIMATELY EUR 13 MILLION LINKED TO DEVALUATION OF CURRENCIE.

Virbac Q1 Revenue Up At 266.5 Million Euros

April 15 (Reuters) - Virbac SA <VIRB.PA>::REVENUE IN Q1 AMOUNTED TO EUR 266.5 MILLION, WITH A SUBSTANTIAL INCREASE OF +17.5% EXCLUDING SENTINEL (+7.6% IN REAL TERMS) COMPARED TO SAME PERIOD IN 2020.A NUMBER OF INDICATORS SEEM TO BE TRENDING VERY POSITIVELY AND SHOULD SUPPORT GROWTH OF ANIMAL HEALTH MARKET IN 2021 AT A MUCH HIGHER LEVEL THAN INITIALLY ANTICIPATED.GROWTH IN Q1 WAS DRIVEN MAINLY BY PERFORMANCE OF ASIA-PACIFIC, EUROPE AND UNITED STATES.REVISING OUR ANNUAL OUTLOOK.ANNUAL OUTLOOK: CURRENTLY ANTICIPATE REVENUE GROWTH AT CONSTANT RATES AND SCOPE OF BETWEEN 6% AND 10%.ANNUAL OUTLOOK: RATIO OF "CURRENT OPERATING PROFIT, BEFORE DEPRECIATION OF ASSETS ARISING FROM ACQUISITIONS" OVER "REVENUE" SHOULD BE BETWEEN 12% AND 14% AT CONSTANT EXCHANGE RATES.ANNUAL OUTLOOK: ANTICIPATE UNFAVORABLE IMPACT OF EXCHANGE RATES ON REVENUE OF APPROXIMATELY EUR 15 MILLION LINKED TO STRONG IMPAIRMENT OF CURRENCIES.

Virbac Sees 2021 Revenue Growth Between 3% And 5%

March 17 (Reuters) - Virbac SA <VIRB.PA>::FY REVENUE FELL 0.4 PERCENT TO 934.2 MILLION EUR.EARLY JULY 2020 DIVESTMENT OF SENTINEL BRANDS IS EXPECTED TO RESULT IN REVENUE DECREASE OF APPROXIMATELY US$55 MILLION AND DECREASE IN EBITA TO REVENUE RATIO OF APPROXIMATELY 3 POINTS ON A PRO FORMA FULL-YEAR BASIS AT TIME OF THE DIVESTMENT.IN 2021, WE ANTICIPATE A GROWTH IN REVENUE AT CONSTANT RATES AND SCOPE OF BETWEEN 3% AND 5%.FOR FY 2021 SEES A RATIO OF "CURRENT OPERATING INCOME, BEFORE DEPRECIATION OF ASSETS ARISING FROM ACQUISITIONS" OVER "REVENUE" WHICH SHOULD BE BETWEEN 10% AND 12% AT CONSTANT EXCHANGE RATE.OUR INVESTMENT LEVEL COULD BE AROUND EUR 60 MILLION PER YEAR OVER 2021-22.

Virbac FY Net Profit Up At EUR 137.5 Mln

March 17 (Reuters) - Virbac SA <VIRB.PA>::REG-VIRBAC 2020 YEAR-END CONSOLIDATED ACCOUNTS.FY REVENUE EUR 934.2 MILLION VERSUS EUR 938.3 MILLION YEAR AGO.FY OPERATING RESULT EUR 185.7 MILLION VERSUS EUR 98.0 MILLION YEAR AGO.FY NET PROFIT GROUP SHARE EUR 137.5 MILLION VERSUS EUR 51.6 MILLION YEAR AGO.THE HEALTH CRISIS COULD HAVE AN IMPACT ON OUR ACTIVITIES IN 2021.FOR THE FINANCIAL YEAR 2020, A PROPOSAL WILL BE MADE TO THE SHAREHOLDERS’ MEETING TO ALLOCATE A NET DIVIDEND OF €0.75 PER SHARE, WITH A NOMINAL VALUE OF €1.25.VIRBAC TAKES OVER ASSETS FROM ELANCO: THESE ASSET TRANSFERS SHOULD HAVE A LIMITED IMPACT ON OUR EBITA AND DO NOT LEAD US TO CHANGE OUR GUIDANCE FOR THE YEAR 2021.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up